Systemic Challenges in Sarcopenia Research: Implications for Meta‐Analytic Reliability and Clinical Translation

ABSTRACT Sarcopenia, the age‐related decline in skeletal muscle mass and strength, is a growing public health concern, yet several meta‐analyses may be unreliable due to methodological and systemic challenges. This article examines issues compromising meta‐analytic validity: flexibility in study design and analysis, lack of control for parameters influencing muscle health, heterogeneity in definitions and measurements, epidemiological pitfalls, impact of comorbidities, and examination of sarcopenia combined with prolonged sedentary lifestyle. Specifically, flexible designs and p‐hacking may inflate spurious findings, while heterogeneity in definitions and measurement methods, often resulting in modest effect sizes, could challenge clinical interpretation. Publication bias may favour positive results, while epidemiological pitfalls, including reverse causality (e.g., sarcopenia as a consequence rather than the cause of conditions) and associative claims (e.g., gut microbiome correlations), may hinder causal inferences. Unadjusted comorbidities, heterogeneous interventions (e.g., combining heterogeneous therapies), comparators (e.g., placebo vs. usual care), and uncontrolled dietary intake and sleep quality may further obscure results. Sarcopenia‐based studies may also be confounded by lifelong sedentary behaviour, as lack of physical activity/exercise history could limit the isolation of age‐related sarcopenia from physical inactivity combined with age‐related sarcopenia. To enhance rigour in meta‐analyses in the field, standardized definitions, pre‐registered protocols, harmonized assessments, comorbidity phenotyping, intervention and comparator stratification, and causal inference techniques seem essential. Well‐controlled longitudinal studies tracking exercise history are warranted, whereas advanced statistical methods and data sharing could improve validity. Overall, these applications may help establish robust evidence to inform tailored clinical interventions and policy decisions for ageing populations.